PLUS1
4.52
0.24 (5.61%)
0.24 (5.61%)
Upgrade to Real-Time
Market Closed
Best deals to access real time data! |
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
Small Cap Pro
Monthly Subscription
for only
|
|
Ultimate Trader (Monthly)
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| CytoDyn Inc (QB) | CYDY | OTCMarkets | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.24 | 5.61% | 4.52 | 15:59:59 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.375 | 4.17 | 4.62 | 4.52 | 4.28 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 4.52 | 4.54 | 0.02 | - | - |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3,023 | 2,781,504 | $ 4.3077 | $ 11,981,968 | - | 0.81 - 10.01 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 15:59:59 | 300 | $ 4.52 | USD |
CytoDyn (QB) Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 2.75B | 608.41M | 377.49M | $ - | $ - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| 27.62M | $ - | 0.00% | - | - |
CytoDyn (QB) News
| Date | Time | Source | News Article |
|---|---|---|---|
| 2/22/2021 | 07:08 | Seeking Alpha | CytoDyn in discussions with regulators after CD12 data in.. |
| 2/22/2021 | 06:18 | InvestorsHub NewsWire | Nextech AR (OTCQB: NEXCF) $13 million Deal, Guidance to.. |
| 2/12/2021 | 06:26 | InvestorsHub NewsWire | Nextech AR (OTCQB: NEXCF) 2021 Guidance $50-60 Million.. |
| 2/05/2021 | 09:08 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) |
| 1/29/2021 | 08:32 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 1/22/2021 | 09:48 | InvestorsHub NewsWire | WSGF's, Vaycaychella, Heats Up In $32 Billion Caribbean.. |
| 1/15/2021 | 16:31 | Edgar (US Regulatory) | Securities Registration Statement (simplified Form) (s-3) |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CYDY Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.32 | 5.41 | 3.85 | 4.38 | 5,360,356 | -0.80 | -15.04% |
| 1 Month | 5.14 | 7.70 | 3.85 | 5.77 | 5,079,207 | -0.62 | -12.06% |
| 3 Months | 2.45 | 7.70 | 2.30 | 5.12 | 5,316,022 | 2.07 | 84.49% |
| 6 Months | 3.79 | 7.70 | 1.63 | 4.25 | 4,142,715 | 0.73 | 19.26% |
| 1 Year | 1.11 | 10.01 | 0.81 | 3.99 | 5,777,940 | 3.41 | 307.21% |
| 3 Years | 0.70 | 10.01 | 0.0552 | 3.31 | 2,459,684 | 3.82 | 545.71% |
| 5 Years | 0.95 | 10.01 | 0.0552 | 3.16 | 1,575,892 | 3.57 | 375.79% |
CytoDyn (QB) Description
| CytoDyn Inc. is a late-stage biotechnology company developing innovative treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of Human Immunodeficiency Virus (HIV), Cancer, and Immunology. |
